"The group is best known in two areas: the life sciences arena, where the firm is considered one of the best in the country, and for its regulatory expertise, which is integrated with its transactional capability."

"This practice spans the corporate and private equity spheres, and stands out for its focus on the life sciences, pharmaceutical and biotech sectors, where it represents a range of major clients."

Chambers USA (2010)

“Their in-depth knowledge is impressive.”

“They have the ability to help clients bolster their presence in the market.”

Chambers Asia (2011)

"The team has unparalleled expertise in the industry – they understand the science and underlying policy issues, and are great at picking up trends."

Chambers UK (2011)

Covington’s life sciences practice integrates the firm’s extensive transactional, regulatory, litigation and intellectual property expertise to provide seamless, integrated advice to meet the specialized needs of life sciences companies around the world.  Our clients include most of the major innovator pharmaceutical and biotechnology companies in the world today, many mid-size and emerging biotechnology, animal health, drug discovery and medical device companies, trade associations for the industry, research institutions and investors in the life sciences sector.

We have one of the world’s leading transactional and corporate law practices in the life sciences industry, supported by leading specialists in related fields, including regulatory, intellectual property and antitrust.  Our transactional lawyers work exclusively on M&A, collaborations and other strategic transactions and commercial arrangements in the life sciences sector.

Our dedicated, multidisciplinary, industry-focused approach allows Covington to offer a level of insight into life sciences transactions that we believe is unique.  We know the key players and are keenly aware of the commercial, regulatory, IP, competition, and other business issues that shape the industry.  We draw on our cross-disciplinary knowledge and skills to help our clients accomplish their immediate needs and better achieve their long-term strategic goals in a cost efficient manner.


  • Law360
    • Firm
    • Individual
      • John Hurvitz - Life Sciences MVP (2012)
  • Chambers Global (2013-2014)
    • Firm
      • Life Sciences, Global-wide
      • Life Sciences, Europe-wide
    • Individual
      • Life Sciences, Corporate/Commercial, Global-wide: John Hurvitz
  • Chambers USA (2013)
    • Firm
      • Life Sciences, Nationwide
      • Life Sciences, CA
    • Individual
      • Life Sciences, Corporate/Commercial, Nationwide: John Hurvitz, Emily Leonard, and James Snipes
      • Life Sciences, Corporate/Commercial, CA: Emily Leonard, James Snipes, and Amy Toro
  • Chambers UK (2015)
    • Firm
      • Life Sciences, UK-wide
      • Life Sciences, Regulatory, UK-wide
      • Life Sciences, Transactional, UK-wide
      • Product Liability, Food, UK-wide
      • Product Liability, Mainly Defendant, UK-wide
    • Individual
      • Life Sciences, Regulatory, UK-wide: Grant Castle
      • Life Sciences, Transactional, UK-wide: Paul Claydon, James Gubbins, Lucinda Osborne, and Daniel Pavin
  • Chambers Asia (2013)
    • Firm
      • Life Sciences (International Firms), China
    • Individual
      • Life Sciences (International Firms), China: Shaoyu Chen and Weishi Li
  • PLC Cross-border Super League
    • Ranked 1st in the Life Sciences Regulatory Super League (2004-2011)
    • Ranked 1st in the Life Sciences Industry Super League (2005-2010)
  • PLC - Life Sciences, Which Law Firm? (2012)
    • Leading: Life Sciences, England, EU, and USA
    • Leading: Commercial and Partnering, England and USA
    • Leading: Corporate, England
    • Highly Recommended: Life Sciences, Belgium
    • Highly Recommended: Corporate, USA
  • PLC - Life Sciences, Which Lawyer? (2012)
    • Commercial and Partnering: John Hurvitz, Emily Leonard, Lucinda Osborne, Daniel Pavin, and James Snipes
    • Corporate: James Beery, Bruce Bennett, Paul Claydon, Ellen Corenswet, James Gubbins, and Natalie Walter
  • Legal 500 US (2013)
    • Firm
      • Healthcare – Life Sciences 
      • Healthcare – Health Insurers
      • Product Liability and Mass Tort Defense – Pharmaceuticals and Medical Devices
    • Individual
      • Healthcare – Life Sciences: Catherine Dargan, Ed Dixon, Ellen Flannery, John Hall, Geoffrey Hobart, John Hurvitz, Richard Kingham, Emily Leonard, Matthew O’Connor, and Peter Safir
      • Healthcare – Health Insurers: Anna Engh and David Goodwin
      • Product Liability and Mass Tort Defense – Pharmaceuticals and Medical Devices: Pat Davies, Michael Imbroscio, and Paul Schmidt
  • Legal 500 UK (2014)
    • Firm
      • Pharmaceuticals and Biotechnology
      • Product Liability – Defendant
    • Individual
      • Pharmaceuticals and Biotechnology: Grant Castle, Paul Claydon, James Gubbins, Lucinda Osborne, and Morag Peberdy
      • Product Liability – Defendant: Grant Castle and Brian Kelly
  • Legal 500 EMEA (2013)
    • Firm
      • EU Regulatory - Pharmaceuticals and Biotechnology
      • EU Regulatory - Food
    • Individual
      • EU Regulatory – Pharmaceuticals and Biotechnology: Peter Bogaert and Cándido García Molyneux
      • EU Regulatory – Food: Peter Bogaert
  • LMG Life Sciences (2012)
    • Firm
      • Lifecycle Firm
      • Highly Recommended: Finance & Transactional, Corporate
      • Highly Recommended: Finance & Transactional, Licensing & Collaboration
    • Individual
      • Finance & Transactional: Edward Britton, Ellen Corenswet, Catherine Dargan, Bruce Deming, Edward Dixon, John Hurvitz, Emily Leonard, James Snipes, and Amy Toro
Print PDF Word Version Print this page


+1 202 662 5319

+1 415 591 7071